C. and /. V1, 7) V2: 3.2 (1.1-3.9) V3: 2.2 (1.2-3.4) t max V1: 1, pp.2-6

. Prednisone, 27) MPA MPAG AcMPAG DN-AUC 0-12 18, pp.152-909

L. Transplantation-non, 119] 7 patients 50±10 years 4.4±3.9 years (0.3-11.5) Steady-state, 1-3 g/day 2.4±0.9 g/day (35.5±14.1 mg/kg/day) r² C 0 -AUC0 -12 = 0.714; r² C 2 -AUC 0-12 = 0.663; r² C 8 -AUC 0-12 = 0.884 ; otherwise, r² = 0.176-0.732 Recommended sparse sampling algorithms: ? log

C. Legend, Cystic fibrosis ? D: Dose ? HTx: Heart transplantation ? KTx: Kidney transplantation ? LTx: Lung transplantation ? N/R: not reported

A. Zuckermann and W. Klepetko, Use of cyclosporine in thoracic transplantation, Transplantation Proceedings, vol.36, issue.2, pp.331-336, 2004.
DOI : 10.1016/j.transproceed.2004.01.024

D. Taylor, L. Edwards, and M. Boucek, Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth Official Adult Heart Transplant Report???2007, The Journal of Heart and Lung Transplantation, vol.26, issue.8, pp.769-781, 2007.
DOI : 10.1016/j.healun.2007.06.004

E. Trulock, J. Christie, and L. Edwards, Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth Official Adult Lung and Heart???Lung Transplantation Report???2007, The Journal of Heart and Lung Transplantation, vol.26, issue.8, pp.782-795, 2007.
DOI : 10.1016/j.healun.2007.06.003

P. Jaksch, A. Kocher, and P. Neuhauser, Monitoring C2 Level Predicts Exposure in Maintenance Lung Transplant Patients Receiving the Microemulsion Formulation of Cyclosporine (Neoral), The Journal of Heart and Lung Transplantation, vol.24, issue.8, pp.1076-1080, 2005.
DOI : 10.1016/j.healun.2003.05.002

P. Galiwango, D. Delgado, and R. Yan, Mycophenolate Mofetil Dose Reduction for Gastrointestinal Intolerance is Associated With Increased Rates of Rejection in Heart Transplant Patients, The Journal of Heart and Lung Transplantation, vol.27, issue.1, pp.72-77, 2008.
DOI : 10.1016/j.healun.2007.10.012

H. Hangler, E. Ruttmann, and C. Geltner, Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation, Clinical Transplantation, vol.27, issue.0, pp.35-40, 2008.
DOI : 10.1097/00007890-199907150-00011

M. Estenne, J. Maurer, and A. Boehler, Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria, The Journal of Heart and Lung Transplantation, vol.21, issue.3, pp.297-310, 2002.
DOI : 10.1016/S1053-2498(02)00398-4

C. Knoop, A. Haverich, and S. Fischer, Immunosuppressive therapy after human lung transplantation, European Respiratory Journal, vol.23, issue.1, pp.159-171, 2004.
DOI : 10.1183/09031936.03.00039203

G. Snell and G. Westall, Immunosuppression for Lung Transplantation, Drugs, vol.22, issue.11, pp.1531-1539, 2007.
DOI : 10.2165/00003495-200767110-00002

M. Cantarovich, E. Elstein, and B. De-varennes, CLINICAL BENEFIT OF NEORAL DOSE MONITORING WITH CYCLOSPORINE 2-HR POST-DOSE LEVELS COMPARED TO TROUGH LEVELS IN STABLE HEART TRANSPLANT PATIENTS, Transplantation, vol.67, issue.7, pp.1839-1842, 1999.
DOI : 10.1097/00007890-199904150-00100

M. Oellerich and V. Armstrong, The Role of Therapeutic Drug Monitoring in Individualizing Immunosuppressive Drug Therapy: Recent Developments, Therapeutic Drug Monitoring, vol.28, issue.6, pp.720-725, 2006.
DOI : 10.1097/FTD.0b013e31802c5cf5

K. Mahalati, P. Belitsky, and I. Sketris, NEORAL MONITORING BY SIMPLIFIED SPARSE SAMPLING AREA UNDER THE CONCENTRATION-TIME CURVE, Transplantation, vol.68, issue.1, pp.55-62, 1999.
DOI : 10.1097/00007890-199907150-00011

A. Lindholm and B. Kahan, Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation, Clinical Pharmacology and Therapeutics, vol.54, issue.2, pp.205-218, 1993.
DOI : 10.1038/clpt.1993.132

G. Levy, C2 Monitoring Strategy for Optimising Cyclosporin Immunosuppression from the Neoral??* Formulation, BioDrugs, vol.1, issue.51, pp.279-290, 2001.
DOI : 10.2165/00063030-200115050-00001

L. Meur, Y. Buchler, M. Thierry, and A. , Individualized Mycophenolate Mofetil Dosing Based on Drug Exposure Significantly Improves Patient Outcomes After Renal Transplantation, American Journal of Transplantation, vol.82, issue.1, pp.2496-2503, 2007.
DOI : 10.1097/00007691-200412000-00005

M. Shafi and P. Pasricha, Post-surgical and obstructive gastroparesis, Current Gastroenterology Reports, vol.98, issue.4, pp.280-285, 2007.
DOI : 10.1007/s11894-007-0031-2

S. Sodhi, J. Guo, and A. Maurer, Gastroparesis After Combined Heart and Lung Transplantation, Journal of Clinical Gastroenterology, vol.34, issue.1, pp.34-39, 2002.
DOI : 10.1097/00004836-200201000-00007

F. Akhlaghi, A. Keogh, and A. Mclachlan, Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors, The Journal of Heart and Lung Transplantation, vol.20, issue.4, pp.431-438, 2001.
DOI : 10.1016/S1053-2498(00)00234-5

F. Akhlaghi, L. Gonzalez, and A. Trull, Association Between Cyclosporine Concentrations at 2 Hours Post-dose and Clinical Outcomes in De Novo Lung Transplant Recipients, The Journal of Heart and Lung Transplantation, vol.24, issue.12, pp.2120-2128, 2005.
DOI : 10.1016/j.healun.2005.05.005

C. Balram, C. Sivathasan, and Y. Cheung, A limited sampling strategy for the estimation of 12-hour Neoral systemic drug exposure in heart transplant recipients, The Journal of Heart and Lung Transplantation, vol.21, issue.9, pp.1016-1021, 2002.
DOI : 10.1016/S1053-2498(02)00419-9

M. Cantarovich, N. Giannetti, and R. Cecere, Impact of cyclosporine 2-h level and mycophenolate mofetil dose on clinical outcomes in de novo heart transplant patients receiving anti-thymocyte globulin induction, Clinical Transplantation, vol.2, issue.2, pp.144-150, 2003.
DOI : 10.1097/00007691-200108000-00001

G. Cooney and A. Johnston, Noeral C-2 monitoring in cardiac transplant patients, Transplantation Proceedings, vol.33, issue.1-2, pp.1572-1575, 2001.
DOI : 10.1016/S0041-1345(00)02598-7

S. Kesten, M. Scavuzzo, and C. Chaparro, Pharmacokinetic profile and variability of cyclosporine versus neoral in patients with cystic fibrosis after lung transplantation, Pharmacotherapy, vol.18, issue.4, pp.847-850, 1998.

C. Knoop, I. Vervier, and P. Thiry, Cyclosporine pharmacokinetics and dose monitoring after lung transplantation: comparison between cystic fibrosis and other conditions, Transplantation, vol.76, issue.4, pp.683-688, 2003.
DOI : 10.1097/01.TP.0000076473.71399.26

M. Reynaud-gaubert, L. Viard, and D. Girault, Improved absorption and bioavailability of cyclosporine A from a microemulsion formulation in lung transplant recipients affected with cystic fibrosis, Transplantation Proceedings, vol.29, issue.5, pp.2450-2453, 1997.
DOI : 10.1016/S0041-1345(97)00446-6

K. Tan, K. Hue, and S. Strickland, Altered Pharmacokinetics of Cyclosporin in Heart-Lung Transplant Recipients with Cystic Fibrosis, Therapeutic Drug Monitoring, vol.12, issue.6, pp.520-524, 1990.
DOI : 10.1097/00007691-199011000-00002

A. Trull, L. Steel, and L. Sharples, Randomized, Trough Blood Cyclosporine Concentration-controlled Trial to Compare the Pharmacodynamics of Sandimmune and Neoral in De Novo Lung Transplant Recipients, Therapeutic Drug Monitoring, vol.21, issue.1, pp.17-26, 1999.
DOI : 10.1097/00007691-199902000-00004

M. Baraldo, F. Pea, and D. Poz, Pharmacokinetics of two oral cyclosporin a formulations in clinically stable heart-transplant patients, Pharmacological Research, vol.43, issue.6, pp.547-551, 2001.
DOI : 10.1006/phrs.2001.0823

J. Ray, A. Keogh, and A. Mclachlan, Decision Support Tool to Individualize Cyclosporine Dose in Stable, Long-term Heart Transplant Recipients Receiving Metabolic Inhibitors: Overcoming Limitations of Cyclosporine C2 Monitoring, The Journal of Heart and Lung Transplantation, vol.25, issue.10, pp.1223-1229, 2006.
DOI : 10.1016/j.healun.2006.07.002

C. Monchaud, A. Rousseau, and F. Leger, Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC0???12 monitoring in cardiac transplant recipients over the first year post-transplantation, European Journal of Clinical Pharmacology, vol.66, issue.12, pp.813-820, 2003.
DOI : 10.1007/s002280050718

A. Rousseau, C. Monchaud, and J. Debord, Bayesian Forecasting of Oral Cyclosporin Pharmacokinetics in Stable Lung Transplant Recipients With and Without Cystic Fibrosis, Therapeutic Drug Monitoring, vol.25, issue.1, pp.28-35, 2003.
DOI : 10.1097/00007691-200302000-00004

J. Parke and B. Charles, NONMEM Population Pharmacokinetic Modeling of Orally Administered Cyclosporine From Routine Drug Monitoring Data After Heart Transplantation, Therapeutic Drug Monitoring, vol.20, issue.3, pp.284-293, 1998.
DOI : 10.1097/00007691-199806000-00008

S. Rosenbaum, G. Baheti, and A. Trull, Population Pharmacokinetics of Cyclosporine in Cardiopulmonary Transplant Recipients, Therapeutic Drug Monitoring, vol.27, issue.2, pp.116-122, 2005.
DOI : 10.1097/01.ftd.0000148448.51225.2c

B. Kahan, J. Dunn, and C. Fitts, REDUCED INTER- AND INTRASUBJECT VARIABILITY IN CYCLOSPORINE PHARMACOKINETICS IN RENAL TRANSPLANT RECIPIENTS TREATED WITH A MICROEMULSION FORMULATION IN CONJUNCTION WITH FASTING, LOW-FAT MEALS, OR HIGH-FAT MEALS1,2, Transplantation, vol.59, issue.4, pp.505-511, 1995.
DOI : 10.1097/00007890-199559040-00011

A. Johnston, O. David, and G. Cooney, Pharmacokinetic validation of neoral absorption profiling, Transplantation Proceedings, vol.32, issue.3, pp.53-56, 2000.
DOI : 10.1016/S0041-1345(00)00864-2

F. Saint-marcoux, P. Marquet, and A. Rousseau, Letter to the Editor, Therapeutic Drug Monitoring, vol.28, issue.1, p.138, 2006.
DOI : 10.1097/01.ftd.0000188016.36982.35

J. Debord, E. Risco, and M. Harel, Application of a Gamma Model of Absorption to Oral Cyclosporin, Clinical Pharmacokinetics, vol.16, issue.5, pp.375-382, 2001.
DOI : 10.2165/00003088-200140050-00004

J. Kobashigawa, S. Katznelson, and H. Laks, Effect of Pravastatin on Outcomes after Cardiac Transplantation, New England Journal of Medicine, vol.333, issue.10, pp.621-627, 1995.
DOI : 10.1056/NEJM199509073331003

F. Akhlaghi, A. Mclachlan, and A. Keogh, Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients, British Journal of Clinical Pharmacology, vol.44, issue.6, pp.537-542, 1997.
DOI : 10.1046/j.1365-2125.1997.t01-1-00625.x

A. Mclachlan and S. Tett, Effect of Metabolic Inhibitors on Cyclosporine Pharmacokinetics Using a Population Approach, Therapeutic Drug Monitoring, vol.20, issue.4, pp.390-395, 1998.
DOI : 10.1097/00007691-199808000-00007

P. Aurora, M. Boucek, and J. Christie, Registry of the International Society for Heart and Lung Transplantation: Tenth Official Pediatric Lung and Heart/Lung Transplantation Report???2007, The Journal of Heart and Lung Transplantation, vol.26, issue.12, pp.1223-1228, 2007.
DOI : 10.1016/j.healun.2007.07.035

. Del-mar-fernandez-de-gatta, D. Santos-buelga, and A. Dominguez-gil, Immunosuppressive Therapy for Paediatric Transplant Patients, Clinical Pharmacokinetics, vol.30, issue.6, pp.115-135, 2002.
DOI : 10.2165/00003088-200241020-00004

G. Kearns, S. Abdel-rahman, and S. Alander, Developmental pharmacology-drug disposition, action, and therapy in infants and children, N Engl J Med, vol.349, issue.12, pp.1157-1167, 2003.

I. Bartelink, C. Rademaker, and A. Schobben, Guidelines on Paediatric Dosing on the Basis of Developmental Physiology and Pharmacokinetic Considerations, Clinical Pharmacokinetics, vol.67, issue.6, pp.1077-1097, 2006.
DOI : 10.2165/00003088-200645110-00003

C. Clardy, T. Schroeder, and S. Myre, Clinical variability of cyclosporine pharmacokinetics in adult and pediatric patients after renal, cardiac, hepatic, and bone-marrow transplants, Clin Chem, vol.34, issue.10, pp.2012-2015, 1988.

K. Tan, A. Trull, and K. Hue, Pharmacokinetics of cyclosporine in heart and lung transplant candidates and recipients with cystic fibrosis and Eisenmenger's syndrome, Clinical Pharmacology and Therapeutics, vol.53, issue.5
DOI : 10.1038/clpt.1993.68

A. Kelman, B. Whiting, and S. Bryson, OPT: a package of computer programs for parameter optimisation in clinical pharmacokinetics., British Journal of Clinical Pharmacology, vol.9, issue.2, pp.247-256, 1982.
DOI : 10.1111/j.1365-2125.1982.tb01969.x

G. Mikhail, H. Eadon, and N. Leaver, An investigation of the pharmacokinetics, toxicity, and clinical efficacy of neoral cyclosporin in cystic fibrosis patients, Transplantation Proceedings, vol.29, issue.1-2, pp.599-601, 1997.
DOI : 10.1016/S0041-1345(96)00319-3

K. Tan, A. Trull, and J. Uttridge, Relative bioavailability of cyclosporin from conventional and microemulsion formulations in heart-lung transplant candidates with cystic fibrosis, European Journal of Clinical Pharmacology, vol.48, issue.3-4, pp.3-4, 1995.
DOI : 10.1007/BF00198313

H. Mathias, F. Ozalp, and M. Will, A Randomized, Controlled Trial of C0- Vs C2-guided Therapeutic Drug Monitoring of Cyclosporine in Stable Heart Transplant Patients, The Journal of Heart and Lung Transplantation, vol.24, issue.12, pp.2137-2143, 2005.
DOI : 10.1016/j.healun.2005.04.019

B. Kahan, P. Keown, and G. Levy, Therapeutic drug monitoring of immunosuppressant drugs in clinical practice, Clinical Therapeutics, vol.24, issue.3, pp.330-350, 2002.
DOI : 10.1016/S0149-2918(02)85038-X

R. Dumont and M. Ensom, Methods for Clinical Monitoring of Cyclosporin in Transplant Patients, Clinical Pharmacokinetics, vol.25, issue.5, pp.427-447, 2000.
DOI : 10.2165/00003088-200038050-00004

S. Solari, L. Goldberg, and D. Denofrio, Cyclosporine Monitoring With 2-Hour Postdose Levels in Heart Transplant Recipients, Therapeutic Drug Monitoring, vol.27, issue.4, pp.417-421, 2005.
DOI : 10.1097/01.ftd.0000159786.10625.85

S. Schubert, H. Abdul-khaliq, and H. Lehmkuhl, Advantages of C2 Monitoring to Avoid Acute Rejection in Pediatric Heart Transplant Recipients, The Journal of Heart and Lung Transplantation, vol.25, issue.6, pp.619-625, 2006.
DOI : 10.1016/j.healun.2006.02.002

M. Cantarovich, J. Besner, and J. Barkun, Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy, Clin Transplant, 1998.

J. Ray, A. Keogh, and A. Mclachlan, Cyclosporin C2 and C0 concentration monitoring in stable, long-term heart transplant recipients receiving metabolic inhibitors, The Journal of Heart and Lung Transplantation, vol.22, issue.7, pp.715-722, 2003.
DOI : 10.1016/S1053-2498(02)00649-6

M. Cantarovich, J. Besner, and D. Fitchett, Efficacy and side-effects of cyclosporine dose monitoring with levels 6 h after the morning dose in heart transplant patients, Clin Transplant, vol.11, issue.5, pp.399-405, 1997.

R. Caruso, N. Perico, and D. Cattaneo, Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients, Clin Chem, vol.47, issue.9, pp.1679-1687, 2001.

P. Halloran, L. Helms, and L. Kung, The temporal profile of calcineurin inhibition by cyclosporine in vivo, Transplantation Nov, vol.15, issue.689, pp.1356-1361, 1999.

B. Kahan, M. Welsh, and L. Rutzky, Challenges in Cyclosporine Therapy: The Role of Therapeutic Monitoring by Area Under the Curve Monitoring, Therapeutic Drug Monitoring, vol.17, issue.6, 1995.
DOI : 10.1097/00007691-199512000-00013

P. Keown, D. Landsberg, and P. Halloran, A RANDOMIZED, PROSPECTIVE MULTICENTER PHARMACOEPIDEMIOLOGIC STUDY OF CYCLOSPORINE MICROEMULSION IN STABLE RENAL GRAFT RECIPIENTS1,2,3, Transplantation, vol.62, issue.12, pp.1744-1752, 1996.
DOI : 10.1097/00007890-199612270-00009

K. Mahalati, P. Belitsky, and K. West, Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study, J Am Soc Nephrol, 2001.

J. Grevel and B. Kahan, Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy, Clin Chem, vol.37, issue.11, pp.1905-1908, 1991.

R. Dumont, N. Partovi, and R. Levy, A limited sampling strategy for cyclosporine area under the curve monitoring in lung transplant recipients, The Journal of Heart and Lung Transplantation, vol.20, issue.8, pp.897-900, 2001.
DOI : 10.1016/S1053-2498(01)00272-8

L. Sheiner and S. Beal, Some suggestions for measuring predictive performance, Journal of Pharmacokinetics and Biopharmaceutics, vol.61, issue.4, pp.503-512, 1981.
DOI : 10.1007/BF01060893

O. David and A. Johnston, Limited Sampling Strategies for Estimating Cyclosporin Area Under the Concentration???Time Curve: Review of Current Algorithms, Therapeutic Drug Monitoring, vol.23, issue.2, pp.100-114, 2001.
DOI : 10.1097/00007691-200104000-00003

F. Leger, J. Debord, L. Meur, and Y. , Maximum A Posteriori Bayesian Estimation of Oral Cyclosporin Pharmacokinetics in Patients with Stable Renal Transplants, Clinical Pharmacokinetics, vol.17, issue.1, pp.71-80, 2002.
DOI : 10.2165/00003088-200241010-00006

A. Rousseau, F. Leger, L. Meur, and Y. , Population Pharmacokinetic Modeling of Oral Cyclosporin Using NONMEM, Therapeutic Drug Monitoring, vol.26, issue.1, pp.23-30, 2004.
DOI : 10.1097/00007691-200402000-00006

H. Bourgoin, G. Paintaud, and M. Buchler, Bayesian estimation of cyclosporin exposure for routine therapeutic drug monitoring in kidney transplant patients, British Journal of Clinical Pharmacology, vol.32, issue.1, pp.18-27, 2005.
DOI : 10.1097/01.TP.0000089006.00653.64

S. Irtan, F. Saint-marcoux, and A. Rousseau, Population Pharmacokinetics and Bayesian Estimator of Cyclosporine in Pediatric Renal Transplant Patients, Therapeutic Drug Monitoring, vol.29, issue.1, pp.96-102, 2007.
DOI : 10.1097/FTD.0b013e3180310f9d

J. Parke and B. Charles, Factors affecting oral cyclosporin disposition after heart transplantation: bootstrap validation of a population pharmacokinetic model, European Journal of Clinical Pharmacology, vol.56, issue.6-7, pp.6-7, 2000.
DOI : 10.1007/s002280000164

A. Nohria, J. Ehtisham, and T. Ramahi, Optimum maintenance trough levels of cyclosporine in heart transplant recipients given corticosteroid-free regimen, J Heart Lung Transplant, vol.17, issue.9, pp.849-853, 1998.

A. Gamel, B. Keevil, and A. Rahman, Cardiac allograft rejection: do trough cyclosporine levels correlate with the grade of histologic rejection?, J Heart Lung Transplant, vol.16, issue.3, pp.268-274, 1997.

A. Trull, K. Hue, and K. Tan, Cross-correlation of cyclosporine concentrations and biochemical measures of kidney and liver function in heart and heart-lung transplant recipients, Clin Chem, vol.36, issue.8, pp.1474-1478, 1990.

A. Trull, N. Best, and K. Tan, Blood Cyclosporin Concentrations but Not Doses Correlate with Acute Changes in Renal Function Following Heart and Heart-Lung Transplantation, Therapeutic Drug Monitoring, vol.14, issue.4, pp.275-280, 1992.
DOI : 10.1097/00007691-199208000-00003

M. Aumente, J. Arizon, and J. Segura, Relationship Between Pharmacokinetic Parameters of Cyclosporin and the Incidence of Acute Rejection After Heart Transplantation, Transplantation Proceedings, vol.37, issue.9, pp.4014-4017, 2005.
DOI : 10.1016/j.transproceed.2005.09.149

V. Monforte, S. Bullich, and L. Pou, Blood cyclosporine C0 and C2 concentrations and cytomegalovirus infections following lung transplantation, Transplantation Proceedings, vol.35, issue.5, pp.1992-1993, 2003.
DOI : 10.1016/S0041-1345(03)00689-4

N. Best, A. Trull, and K. Tan, Blood cyclosporin concentrations and the short-term risk of lung rejection following heart-lung transplantation., British Journal of Clinical Pharmacology, vol.319, issue.2, pp.513-520, 1992.
DOI : 10.1111/j.1365-2125.1992.tb05657.x

G. Levy, P. Burra, and A. Cavallari, Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2)1, Transplantation, vol.73, issue.6
DOI : 10.1097/00007890-200203270-00022

S. Stefoni, K. Midtved, and E. Cole, Efficacy and Safety Outcomes Among De Novo Renal Transplant Recipients Managed by C2 Monitoring of Cyclosporine A Microemulsion: Results of a 12-Month, Randomized, Multicenter Study, Transplantation, vol.79, issue.5, pp.577-583, 2005.
DOI : 10.1097/01.TP.0000153158.91683.34

E. Thervet, P. Pfeffer, and M. Scolari, Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion, Transplantation, vol.76, issue.6, pp.903-908, 2003.
DOI : 10.1097/01.TP.0000089006.00653.64

M. Baraldo, A. Francesconi, and F. Barbone, C2 monitoring of cyclosporine in stable heart transplant patients after two daily and three daily doses, Transplantation Proceedings, vol.34, issue.8, 2002.
DOI : 10.1016/S0041-1345(02)03699-0

A. Caforio, F. Tona, and S. Piaserico, C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients, Transplant International, vol.35, issue.1, 2005.
DOI : 10.1097/00007890-199802270-00009

D. Delgado, V. Rao, and J. Hamel, Monitoring of Cyclosporine 2-Hour Post-Dose Levels in Heart Transplantation: Improvement in Clinical Outcomes, The Journal of Heart and Lung Transplantation, vol.24, issue.9, pp.1343-1346, 2005.
DOI : 10.1016/j.healun.2004.08.002

A. Glanville, J. Morton, and C. Aboyoun, Cyclosporine C2 monitoring improves renal dysfunction after lung transplantation, The Journal of Heart and Lung Transplantation, vol.23, issue.10, pp.1170-1174, 2004.
DOI : 10.1016/j.healun.2003.08.032

A. Glanville, C. Aboyoun, and J. Morton, Cyclosporine C2 Target Levels and Acute Cellular Rejection After Lung Transplantation, The Journal of Heart and Lung Transplantation, vol.25, issue.8, pp.928-934, 2006.
DOI : 10.1016/j.healun.2006.03.020

M. Cantarovich, M. Quantz, and E. Elstein, Neoral dose monitoring with cyclosporine 2-hour postdose levels in heart transplant patients receiving anti-thymocyte globulin induction, Transplantation Proceedings, vol.32, issue.2, pp.446-448, 2000.
DOI : 10.1016/S0041-1345(00)00842-3

M. Cantarovich, N. Giannetti, and R. Cecere, Relationship between endomyocardial biopsy score and cyclosporine 2-h post-dose levels (C2) in heart transplant patients receiving anti-thymocyte globulin induction, Clinical Transplantation, vol.6, issue.2, pp.148-151, 2004.
DOI : 10.1097/00007890-200101150-00012

M. Cantarovich, H. Ross, and J. Arizon, Benefit of Neoral C2 monitoring in de novo cardiac transplant recipients receiving basiliximab induction, Transplantation, 2008.

J. Morton, C. Aboyoun, and M. Malouf, Enhanced clinical utility of De Novo cyclosporine C2 monitoring after lung transplantation, The Journal of Heart and Lung Transplantation, vol.23, issue.9, 2004.
DOI : 10.1016/j.healun.2003.08.008

F. Diciolla, S. Scolletta, and L. Berti, C2 and C0 Values for Monitoring Cyclosporine Therapy in Stable Heart Transplant Recipients, Transplantation Proceedings, vol.37, issue.2, pp.1355-1359, 2005.
DOI : 10.1016/j.transproceed.2005.01.079

N. Briffa and R. Morris, New immunosuppressive regimens in lung transplantation, European Respiratory Journal, vol.10, issue.11, pp.2630-2637, 1997.
DOI : 10.1183/09031936.97.10112630

D. Taylor, M. Barr, and B. Meiser, Suggested guidelines for the use of tacrolimus in cardiac transplant recipients, The Journal of Heart and Lung Transplantation, vol.20, issue.7, pp.734-738, 2001.
DOI : 10.1016/S1053-2498(00)00222-9

H. Treede, W. Klepetko, and H. Reichenspurner, Tacrolimus versus cyclosporine after lung transplantation: a prospective, open, randomized two-center trial comparing two different immunosuppressive protocols, The Journal of Heart and Lung Transplantation, vol.20, issue.5, pp.511-517, 2001.
DOI : 10.1016/S1053-2498(01)00244-3

H. Reichenspurner, Overview of tacrolimus-based immunosuppression after heart or lung transplantation, The Journal of Heart and Lung Transplantation, vol.24, issue.2, pp.119-130, 2005.
DOI : 10.1016/j.healun.2004.02.022

E. Garrity, J. Hertz, M. Trulock, and E. , Suggested guidelines for the use of tacrolimus in lung-transplant recipients, J Heart Lung Transplant, vol.18, issue.3, pp.175-176, 1999.

H. Reichenspurner, F. Kur, and H. Treede, OPTIMIZATION OF THE IMMUNOSUPPRESSIVE PROTOCOL AFTER LUNG TRANSPLANTATION1, Transplantation, vol.68, issue.1, pp.67-71, 1999.
DOI : 10.1097/00007890-199907150-00013

N. Undre and A. Schafer, Factors Affecting the Pharmacokinetics of Tacrolimus in the First Year After Renal Transplantation, Transplantation Proceedings, vol.30, issue.4, pp.1261-1263, 1998.
DOI : 10.1016/S0041-1345(98)00234-6

C. Staatz and S. Tett, Clinical Pharmacokinetics and Pharmacodynamics of Tacrolimus in Solid Organ Transplantation, Clinical Pharmacokinetics, vol.33, issue.3, pp.623-53, 2004.
DOI : 10.2165/00003088-200443100-00001

M. Regazzi, M. Rinaldi, and M. Molinaro, Clinical Pharmacokinetics of Tacrolimus in Heart Transplant Recipients, Therapeutic Drug Monitoring, vol.21, issue.1, pp.2-7, 1999.
DOI : 10.1097/00007691-199902000-00002

N. Undre and P. Stevenson, Pharmacokinetics of tacrolimus in heart transplantation, Transplantation Proceedings, vol.34, issue.5, pp.1836-1838, 2002.
DOI : 10.1016/S0041-1345(02)03097-X

C. Wang, W. Ko, and N. Chou, Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: A comparison with cyclosporine neoral, Transplantation Proceedings, vol.36, issue.8, pp.2386-2387, 2004.
DOI : 10.1016/j.transproceed.2004.08.053

W. Aidong, C. Zhenjie, and L. Tong, Therapeutic drug monitoring of tacrolimus in early stage after heart transplantation, Transplantation Proceedings, vol.36, issue.8, pp.2388-2389, 2004.
DOI : 10.1016/j.transproceed.2004.06.037

N. Undre and A. Schafer, Factors Affecting the Pharmacokinetics of Tacrolimus in the First Year After Renal Transplantation, Transplantation Proceedings, vol.30, issue.4, pp.1261-1263, 1998.
DOI : 10.1016/S0041-1345(98)00234-6

K. Napoli, Is Microparticle Enzyme-Linked Immunoassay (MEIA) Reliable for Use in Tacrolimus TDM? Comparison of MEIA to Liquid Chromatography With Mass Spectrometric Detection Using Longitudinal Trough Samples From Transplant Recipients, Therapeutic Drug Monitoring, vol.28, issue.4, pp.491-504, 2006.
DOI : 10.1097/00007691-200608000-00003

N. Brown, C. Gonde, and J. Adams, Low Hematocrit and Serum Albumin Concentrations Underlie the Overestimation of Tacrolimus Concentrations by Microparticle Enzyme Immunoassay versus Liquid Chromatography-Tandem Mass Spectrometry, Clinical Chemistry, vol.51, issue.3, pp.586-592, 2005.
DOI : 10.1373/clinchem.2004.043950

A. Rubio, M. Prado, J. , L. Malo-de-molina, and M. , Clinical pharmacokinetics of tacrolimus in heart transplantation: new strategies of monitoring, Transplantation Proceedings, vol.35, issue.5, pp.1988-1991, 2003.
DOI : 10.1016/S0041-1345(03)00656-0

C. Knoop, P. Thiry, and F. Saint-marcoux, Tacrolimus Pharmacokinetics and Dose Monitoring After Lung Transplantation for Cystic Fibrosis and Other Conditions, American Journal of Transplantation, vol.43, issue.6, pp.1477-1482, 2005.
DOI : 10.1097/00007890-200205151-00003

J. Sgrosso, G. Araujo, and M. Vazquez, Tacrolimus pharmacokinetics in heart transplant, Transplantation Proceedings, vol.34, issue.1, pp.142-143, 2002.
DOI : 10.1016/S0041-1345(01)02706-3

F. Saint-marcoux, C. Knoop, and J. Debord, Pharmacokinetic Study of Tacrolimus in Cystic Fibrosis and Non-Cystic Fibrosis Lung Transplant Patients and Design of Bayesian Estimators Using Limited Sampling Strategies, Clinical Pharmacokinetics, vol.21, issue.4, pp.1317-1328, 2005.
DOI : 10.2165/00003088-200544120-00010

W. Lemahieu, B. Maes, and K. Verbeke, Cytochrome P450 3A4 and P-glycoprotein Activity and Assimilation of Tacrolimus in Transplant Patients with Persistent Diarrhea, American Journal of Transplantation, vol.16, issue.6
DOI : 10.1177/00912700122009999

J. Morton, L. Kear, and S. Williamson, Trough levels are inadequate for monitoring tacrolimus pharmacokinetics in lung transplantation, The Journal of Heart and Lung Transplantation, vol.21, issue.1, p.144, 2002.
DOI : 10.1016/S1053-2498(01)00682-9

M. Molinaro, M. Regazzi, and S. Pasquino, Pharmacokinetics of tacrolimus during the early phase after heart transplantation, Transplantation Proceedings, vol.33, issue.3, pp.2386-2389, 2001.
DOI : 10.1016/S0041-1345(01)02032-2

D. Shitrit, J. Ollech, and A. Ollech, Itraconazole Prophylaxis in Lung Transplant Recipients Receiving Tacrolimus (FK 506): Efficacy and Drug Interaction, The Journal of Heart and Lung Transplantation, vol.24, issue.12, pp.2148-2152, 2005.
DOI : 10.1016/j.healun.2005.05.003

S. Walker, S. Habib, and M. Rose, Clinical Use and Bioavailability of Tacrolimus in Heart-Lung and Double Lung Transplant Recipients With Cystic Fibrosis, Transplantation Proceedings, vol.30, issue.4, pp.1519-1520, 1998.
DOI : 10.1016/S0041-1345(98)00341-8

C. Staatz and S. Tett, Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Solid Organ Transplant Recipients, Clinical Pharmacokinetics, vol.18, issue.2, pp.13-58, 2007.
DOI : 10.2165/00003088-200746010-00002

M. Ensom, N. Partovi, and D. Decarie, Pharmacokinetics and Protein Binding of Mycophenolic Acid in Stable Lung Transplant Recipients, Therapeutic Drug Monitoring, vol.24, issue.2, pp.310-314, 2002.
DOI : 10.1097/00007691-200204000-00013

T. Van-gelder, L. Meur, Y. Shaw, and L. , Therapeutic Drug Monitoring of Mycophenolate Mofetil in Transplantation, Therapeutic Drug Monitoring, vol.28, issue.2, pp.145-154, 2006.
DOI : 10.1097/01.ftd.0000199358.80013.bd

M. Baraldo, M. Isola, and M. Feruglio, Therapeutic Mycophenolic Acid Monitoring by Means of Limited Sampling Strategy in Orthotopic Heart Transplant Patients, Transplantation Proceedings, vol.37, issue.5, pp.2240-2243, 2005.
DOI : 10.1016/j.transproceed.2005.03.090

V. Armstrong, G. Tenderich, and M. Shipkova, Pharmacokinetics and Bioavailability of Mycophenolic Acid After Intravenous Administration and Oral Administration of Mycophenolate Mofetil to Heart Transplant Recipients, Therapeutic Drug Monitoring, vol.27, issue.3, pp.315-321, 2005.
DOI : 10.1097/01.ftd.0000163949.40686.0f

E. Vidal, C. Cantarell, and L. Capdevila, Mycophenolate Mofetil Pharmacokinetics in Transplant Patients Receiving Cyclosporine or Tacrolimus in Combination Therapy, Pharmacology & Toxicology, vol.87, issue.4, pp.182-184, 2000.
DOI : 10.1034/j.1600-0773.2000.pto870407.x

M. Ensom, N. Partovi, and D. Decarie, Mycophenolate Pharmacokinetics in Early Period Following Lung or Heart Transplantation, Annals of Pharmacotherapy, vol.50, issue.12, pp.1761-1767, 2003.
DOI : 10.1038/clpt.1993.68

D. Kaufman, R. Shapiro, and W. Cherikh, Immunosuppression: practice and trends, American Journal of Transplantation, vol.76, issue.4, pp.38-53, 2004.
DOI : 10.1111/j.1600-6135.2004.00397.x

L. Pou, M. Brunet, and C. Cantarell, Mycophenolic Acid Plasma Concentrations: Influence of Comedication, Therapeutic Drug Monitoring, vol.23, issue.1, pp.35-38, 2001.
DOI : 10.1097/00007691-200102000-00007

H. Eisen, J. Kobashigawa, and A. Keogh, Three-Year Results of a Randomized, Double-Blind, Controlled Trial of Mycophenolate Mofetil Versus Azathioprine in Cardiac Transplant Recipients, The Journal of Heart and Lung Transplantation, vol.24, issue.5, pp.517-525, 2005.
DOI : 10.1016/j.healun.2005.02.002

J. Kobashigawa, L. Miller, and D. Renlund, A RANDOMIZED ACTIVE-CONTROLLED TRIAL OF MYCOPHENOLATE MOFETIL IN HEART TRANSPLANT RECIPIENTS1, Transplantation, vol.66, issue.4, pp.507-515, 1998.
DOI : 10.1097/00007890-199808270-00016

B. Meiser, M. Pfeiffer, and D. Schmidt, Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring, The Journal of Heart and Lung Transplantation, vol.18, issue.2, pp.143-149, 1999.
DOI : 10.1016/S1053-2498(98)00002-3

L. Ting, N. Partovi, and R. Levy, Pharmacokinetics of Mycophenolic Acid and its Phenolic-Glucuronide and Acyl Glucuronide Metabolites in Stable Thoracic Transplant Recipients, Therapeutic Drug Monitoring, vol.30, issue.3, pp.282-291, 2008.
DOI : 10.1097/FTD.0b013e318166eba0

E. Devyatko, M. Ploner, and A. Zuckermann, Value of mycophenolic acid trough level monitoring after lung transplantation, Transplantation Proceedings, vol.34, issue.5, pp.1881-1883, 2002.
DOI : 10.1016/S0041-1345(02)03107-X

D. Denofrio, E. Loh, and A. Kao, Mycophenolic acid concentrations are associated with cardiac allograft rejection, The Journal of Heart and Lung Transplantation, vol.19, issue.11, pp.1071-1076, 2000.
DOI : 10.1016/S1053-2498(00)00191-1

L. Shaw, M. Korecka, and D. Denofrio, Pharmacokinetic, pharmacodynamic, and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients, Clinical Biochemistry, vol.34, issue.1, pp.17-22, 2001.
DOI : 10.1016/S0009-9120(00)00184-3

A. Dosch, P. Ehlermann, and A. Koch, A comparison of measured trough levels and abbreviated AUC estimation by limited sampling strategies for monitoring mycophenolic acid exposure in stable heart transplant patients receiving cyclosporin A???Containing and cyclosporin A???Free immunosuppressive regimens, Clinical Therapeutics, vol.28, issue.6, 2006.
DOI : 10.1016/j.clinthera.2006.06.015

V. Mardigyan, N. Giannetti, and R. Cecere, Best Single Time Points to Predict the Area-Under-the-Curve in Long-Term Heart Transplant Patients Taking Mycophenolate Mofetil in Combination with Cyclosporine or Tacrolimus, The Journal of Heart and Lung Transplantation, vol.24, issue.10, pp.1614-1618, 2005.
DOI : 10.1016/j.healun.2004.12.112

R. Gajarski, D. Crowley, and M. Zamberlan, Lack of Correlation Between MMF Dose and MPA Level in Pediatric and Young Adult Cardiac Transplant Patients: Does the MPA Level Matter?1, American Journal of Transplantation, vol.48, issue.9, pp.1495-1500, 2004.
DOI : 10.1177/00912700022009143

M. Cantarovich, N. Giannetti, and R. Cecere, Time points predictors of cyclosporine microemulsion and of mycophenolic acid area-under-the-curve (0-12 hr) in long-term heart transplant patients, Am J Transplant, vol.3, issue.S5, p.168, 2003.

L. Ting, N. Partovi, and R. Levy, Limited Sampling Strategy for Predicting Area Under the Concentration-Time Curve of Mycophenolic Acid in Adult Lung Transplant Recipients, Pharmacotherapy, vol.19, issue.9, pp.1232-1240, 2006.
DOI : 10.2165/00003088-200241050-00001

M. Yamani, R. Starling, and M. Goormastic, THE IMPACT OF ROUTINE MYCOPHENOLATE MOFETIL DRUG MONITORING ON THE TREATMENT OF CARDIAC ALLOGRAFT REJECTION, Transplantation, vol.69, issue.11, pp.2326-2330, 2000.
DOI : 10.1097/00007890-200006150-00018

R. Bullingham, A. Nicholls, and B. Kamm, Clinical Pharmacokinetics of Mycophenolate Mofetil, Clinical Pharmacokinetics, vol.34, issue.6, pp.429-455, 1998.
DOI : 10.2165/00003088-199834060-00002

A. Premaud, J. Debord, and A. Rousseau, A Double Absorption-Phase Model Adequately Describes Mycophenolic Acid Plasma Profiles in De Novo Renal Transplant Recipients Given Oral Mycophenolate Mofetil, Clinical Pharmacokinetics, vol.23, issue.6, pp.837-847, 2005.
DOI : 10.2165/00003088-200544080-00005

M. Gerbase, M. Fathi, and A. Spiliopoulos, Pharmacokinetics of mycophenolic acid associated with calcineurin inhibitors: long-term monitoring in stable lung recipients with and without cystic fibrosis, The Journal of Heart and Lung Transplantation, vol.22, issue.5, pp.587-590, 2003.
DOI : 10.1016/S1053-2498(02)01159-2

X. Cussonneau, M. Bolon-larger, and C. Prunet-spano, Relationship between MPA free fraction and free MPAG concentrations in heart transplant recipients based on simultaneous HPLC quantification of the target compounds in human plasma, Journal of Chromatography B, vol.852, issue.1-2, pp.674-678, 2007.
DOI : 10.1016/j.jchromb.2007.02.038

N. Picard, D. Ratanasavanh, and A. Premaud, IDENTIFICATION OF THE UDP-GLUCURONOSYLTRANSFERASE ISOFORMS INVOLVED IN MYCOPHENOLIC ACID PHASE II METABOLISM, Drug Metabolism and Disposition, vol.33, issue.1, pp.139-146, 2005.
DOI : 10.1124/dmd.104.001651

M. Shipkova, V. Armstrong, and E. Wieland, Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil, British Journal of Pharmacology, vol.350, issue.5, pp.1075-1082, 1999.
DOI : 10.1038/sj.bjp.0702399

M. Shipkova, C. Strassburg, and F. Braun, Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes, British Journal of Pharmacology, vol.21, issue.5, pp.1027-1034, 2001.
DOI : 10.1038/sj.bjp.0703898

N. Picard, T. Cresteil, and A. Premaud, Characterization of a Phase 1 Metabolite of Mycophenolic Acid Produced by CYP3A4/5, Therapeutic Drug Monitoring, vol.26, issue.6, pp.600-608, 2004.
DOI : 10.1097/00007691-200412000-00004

E. Schutz, M. Shipkova, and V. Armstrong, Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil, Clin Chem, vol.45, issue.3, pp.419-422, 1999.

R. Mandla, P. Line, and K. Midtvedt, Automated Determination of Free Mycophenolic Acid and Its Glucuronide in Plasma From Renal Allograft Recipients, Therapeutic Drug Monitoring, vol.25, issue.3, pp.407-414, 2003.
DOI : 10.1097/00007691-200306000-00025

M. Shipkova, V. Armstrong, and L. Weber, Pharmacokinetics and Protein Adduct Formation of the Pharmacologically Active Acyl Glucuronide Metabolite of Mycophenolic Acid in Pediatric Renal Transplant Recipients, Therapeutic Drug Monitoring, vol.24, issue.3, pp.390-399, 2002.
DOI : 10.1097/00007691-200206000-00011

K. Zucker, A. Rosen, and A. Tsaroucha, Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings, Transplant Immunology, vol.5, issue.3, pp.225-232, 1997.
DOI : 10.1016/S0966-3274(97)80042-1

B. Meiser, J. Groetzner, and I. Kaczmarek, Tacrolimus or Cyclosporine: Which Is the Better Partner for Mycophenolate Mofetil in Heart Transplant Recipients?, Transplantation, vol.78, issue.4, pp.591-598, 2004.
DOI : 10.1097/01.TP.0000129814.52456.25

J. Groetzner, B. Meiser, and J. Schirmer, Tacrolimus/mycophenolate mofetil vs cyclosporine/mycophenolate mofetil: comparison of mycophenolate acid trough levels and coronary vasomotor function, The Journal of Heart and Lung Transplantation, vol.20, issue.2, p.191, 2001.
DOI : 10.1016/S1053-2498(00)00398-3

K. Zucker, A. Tsaroucha, and L. Olson, Evidence That Tacrolimus Augments the Bioavailability of Mycophenolate Mofetil Through the Inhibition of Mycophenolic Acid Glucuronidation, Therapeutic Drug Monitoring, vol.21, issue.1, pp.35-43, 1999.
DOI : 10.1097/00007691-199902000-00006

S. Gregoor, P. Van-gelder, T. Hesse, and C. , Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: a cross-sectional study, Nephrology Dialysis Transplantation, vol.14, issue.3, pp.706-708, 1999.
DOI : 10.1093/ndt/14.3.706

T. Van-gelder, J. Klupp, and M. Barten, Comparison of the Effects of Tacrolimus and Cyclosporine on the Pharmacokinetics of Mycophenolic Acid, Therapeutic Drug Monitoring, vol.23, issue.2, 2001.
DOI : 10.1097/00007691-200104000-00005

D. Cattaneo, N. Perico, and F. Gaspari, Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation, Kidney International, vol.62, issue.3, pp.1060-1067, 2002.
DOI : 10.1046/j.1523-1755.2002.00531.x

D. Cattaneo, N. Perico, and F. Gaspari, Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation, Kidney International, vol.62, issue.3, pp.1060-1067, 2002.
DOI : 10.1046/j.1523-1755.2002.00531.x

G. Filler, J. Drick-peart, and U. Christians, Pharmacokinetics of Mycophenolate Mofetil and Sirolimus in Children, Therapeutic Drug Monitoring, vol.30, issue.2, pp.138-142, 2008.
DOI : 10.1097/FTD.0b013e31816ba73a

A. Dipchand, P. B. Mccrindle, and B. , Mycophenolic acid levels in pediatric heart transplant recipients receiving mycophenolate mofetil, The Journal of Heart and Lung Transplantation, vol.20, issue.10, pp.1035-1043, 2001.
DOI : 10.1016/S1053-2498(01)00305-9

L. Ting, N. Partovi, and R. Levy, Pharmacokinetics of Mycophenolic Acid and Its Glucuronidated Metabolites in Stable Lung Transplant Recipients, Annals of Pharmacotherapy, vol.28, issue.9, pp.1509-1516, 2006.
DOI : 10.1345/aph.1H149

S. Knight and P. Morris, Does the Evidence Support the Use of Mycophenolate Mofetil Therapeutic Drug Monitoring in Clinical Practice? A Systematic Review, Transplantation, vol.85, issue.12, pp.1675-1685, 2008.
DOI : 10.1097/TP.0b013e3181744199

B. Cantin, N. Giannetti, and H. Parekh, Mycophenolic acid concentrations in long-term heart transplant patients: relationship with calcineurin antagonists and acute rejection, Clinical Transplantation, vol.87, issue.3, pp.196-201, 2002.
DOI : 10.1097/00007691-200104000-00005

D. Kuypers, H. De-jonge, and M. Naesens, Current target ranges of mycophenolic acid exposure and drug-related adverse events: A 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients, Clinical Therapeutics, vol.30, issue.4, pp.673-683, 2008.
DOI : 10.1016/j.clinthera.2008.04.014

B. Meiser, M. Pfeiffer, and D. Schmidt, The efficacy of the combination of tacrolimus and mycophenolate mofetil for prevention of acute myocardial rejection is dependent on routine monitoring of mycophenolic acid trough acid levels, Transplantation Proceedings, vol.31, issue.1-2, pp.84-87, 1999.
DOI : 10.1016/S0041-1345(98)01448-1

T. Van-gelder, L. Hilbrands, and Y. Vaurenterghem, A RANDOMIZED DOUBLE-BLIND, MULTICENTER PLASMA CONCENTRATION CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF ORAL MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION AFTER KIDNEY TRANSPLANTATION1, Transplantation, vol.68, issue.2, pp.261-266, 1999.
DOI : 10.1097/00007890-199907270-00018

I. Kaczmarek, A. Bigdeli, and M. Vogeser, Defining Algorithms for Efficient Therapeutic Drug Monitoring of Mycophenolate Mofetil in Heart Transplant Recipients, Therapeutic Drug Monitoring, vol.PAP, issue.4, pp.419-427, 2008.
DOI : 10.1097/FTD.0b013e31817d7064

A. Premaud, L. Meur, Y. Debord, and J. , Maximum A Posteriori Bayesian Estimation of Mycophenolic Acid Pharmacokinetics in Renal Transplant Recipients at Different Postgrafting Periods, Therapeutic Drug Monitoring, vol.27, issue.3, pp.354-361, 2005.
DOI : 10.1097/01.ftd.0000162231.90811.38

L. Guellec, C. Bourgoin, H. Buchler, and M. , Population Pharmacokinetics and Bayesian Estimation of Mycophenolic Acid Concentrations in Stable Renal Transplant Patients, Clinical Pharmacokinetics, vol.20, issue.6, pp.253-266, 2004.
DOI : 10.2165/00003088-200443040-00004

C. Hesse, P. Vantrimpont, and I. Van-riemsdijk-van-overbeeke, The value of routine monitoring of mycophenolic acid plasma levels after clinical heart transplantation, Transplantation Proceedings, vol.33, issue.3, pp.2163-2164, 2001.
DOI : 10.1016/S0041-1345(01)01927-3

M. Shipkova, H. Beck, and A. Voland, Identification of protein targets for mycophenolic acid acyl glucuronide in rat liver and colon tissue, PROTEOMICS, vol.4, issue.9, 2004.
DOI : 10.1002/pmic.200300836

M. Shipkova, E. Wieland, and E. Schutz, The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes, Transplantation Proceedings, vol.33, issue.1-2, pp.1080-1081, 2001.
DOI : 10.1016/S0041-1345(00)02424-6

D. Kuypers, K. Claes, and P. Evenepoel, Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients, Clinical Pharmacology & Therapeutics, vol.75, issue.5, 2004.
DOI : 10.1016/j.clpt.2003.12.009

C. Poirier, Promise of neoral C2, basiliximab, and everolimus in lung transplantation, Transplantation Proceedings, vol.36, issue.2, pp.509-513, 2004.
DOI : 10.1016/j.transproceed.2004.01.045

S. Stenton, N. Partovi, and M. Ensom, Sirolimus, Clinical Pharmacokinetics, vol.14, issue.12, pp.769-786, 2005.
DOI : 10.2165/00003088-200544080-00001

T. Mcwilliams, B. Levvey, and P. Russell, Interstitial pneumonitis associated with sirolimus: a dilemma for lung transplantation, The Journal of Heart and Lung Transplantation, vol.22, issue.2, pp.210-213, 2003.
DOI : 10.1016/S1053-2498(02)00564-8

M. King-biggs, J. Dunitz, and S. Park, Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation, Transplantation, vol.75, issue.9, 2003.
DOI : 10.1097/01.TP.0000064083.02120.2C

A. Zuckermann, N. Manito, and E. Epailly, Multidisciplinary Insights on Clinical Guidance for the Use of Proliferation Signal Inhibitors in Heart Transplantation, The Journal of Heart and Lung Transplantation, vol.27, issue.2, pp.141-149, 2008.
DOI : 10.1016/j.healun.2007.08.014

H. Zahir, A. Keogh, and F. Akhlaghi, Apparent Clearance of Sirolimus in Heart Transplant Recipients: Impact of Primary Diagnosis and Serum Lipids, Therapeutic Drug Monitoring, vol.28, issue.6, pp.614-622, 2006.
DOI : 10.1097/01.ftd.0000246765.05248.fa

K. Mahalati and B. Kahan, Clinical Pharmacokinetics of Sirolimus, Clinical Pharmacokinetics, vol.33, issue.8, pp.573-585, 2001.
DOI : 10.2165/00003088-200140080-00002

A. Keogh, M. Richardson, and P. Ruygrok, Sirolimus in De Novo Heart Transplant Recipients Reduces Acute Rejection and Prevents Coronary Artery Disease at 2 Years: A Randomized Clinical Trial, Circulation, vol.110, issue.17, pp.2694-2700, 2004.
DOI : 10.1161/01.CIR.0000136812.90177.94

M. Zucker, D. Baran, and L. Arroyo, De Novo Immunosuppression With Sirolimus and Tacrolimus in Heart Transplant Recipients Compared With Cyclosporine and Mycophenolate Mofetil: A One-Year Follow-Up Analysis, Transplantation Proceedings, vol.37, issue.5, pp.2231-2239, 2005.
DOI : 10.1016/j.transproceed.2005.03.086

J. Groetzner, B. Meiser, and P. Landwehr, Mycophenolate mofetil and sirolimus as calcineurin inhibitor-free immunosuppression for late cardiac-transplant recipients with chronic renal failure, Transplantation, vol.77, issue.4, pp.568-574, 2004.
DOI : 10.1097/01.TP.0000103740.98095.14

J. Zimmerman, G. Ferron, and H. Lim, The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin), J Clin Pharmacol, vol.39, issue.11, pp.1155-1161, 1999.

N. Djebli, A. Rousseau, and G. Hoizey, Sirolimus Population Pharmacokinetic/Pharmacogenetic Analysis and Bayesian Modelling in Kidney Transplant Recipients, Clinical Pharmacokinetics, vol.44, issue.11, pp.1135-1148, 2006.
DOI : 10.2165/00003088-200645110-00007

J. Zimmerman, Exposure-response relationships and drug interactions of sirolimus, The AAPS Journal, vol.6, issue.4, p.28, 2004.
DOI : 10.1208/aapsj060428

V. Mabasa and M. Ensom, The Role of Therapeutic Monitoring of Everolimus in Solid Organ Transplantation, Therapeutic Drug Monitoring, vol.27, issue.5, pp.666-676, 2005.
DOI : 10.1097/01.ftd.0000175911.70172.2e

H. Eisen, E. Tuzcu, and R. Dorent, Everolimus for the Prevention of Allograft Rejection and Vasculopathy in Cardiac-Transplant Recipients, New England Journal of Medicine, vol.349, issue.9, pp.847-858, 2003.
DOI : 10.1056/NEJMoa022171

G. Snell, V. Valentine, and P. Vitulo, Everolimus Versus Azathioprine in Maintenance Lung Transplant Recipients: An International, Randomized, Double-Blind Clinical Trial, American Journal of Transplantation, vol.55, issue.1, pp.169-177, 2006.
DOI : 10.1016/j.healun.2003.08.008

G. Kirchner, I. Meier-wiedenbach, and M. Manns, Clinical Pharmacokinetics of Everolimus, Clinical Pharmacokinetics, vol.33, issue.2, pp.83-95, 2004.
DOI : 10.2165/00003088-200443020-00002

J. Kovarik, A. Noe, and S. Berthier, Clinical Development of an Everolimus Pediatric Formulation: Relative Bioavailability, Food Effect, and Steady-State Pharmacokinetics, The Journal of Clinical Pharmacology, vol.73, issue.suppl. 1, pp.141-147, 2003.
DOI : 10.1177/0091270002239822

J. Kovarik, C. Hsu, and L. Mcmahon, Population pharmacokinetics of everolimus in de novo renal transplant patients: Impact of ethnicity and comedications, Clinical Pharmacology & Therapeutics, vol.70, issue.3, pp.247-254, 2001.
DOI : 10.1067/mcp.2001.118022

J. Kovarik, H. Eisen, and R. Dorent, Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure, The Journal of Heart and Lung Transplantation, vol.22, issue.10, pp.1117-1125, 2003.
DOI : 10.1016/S1053-2498(02)01221-4

J. Kovarik, G. Snell, and V. Valentine, Everolimus in Pulmonary Transplantation: Pharmacokinetics and Exposure???Response Relationships, The Journal of Heart and Lung Transplantation, vol.25, issue.4, 2006.
DOI : 10.1016/j.healun.2005.12.001

G. Brandhorst, G. Tenderich, and A. Zittermann, Everolimus Exposure in Cardiac Transplant Recipients is Influenced by Concomitant Calcineurin Inhibitor, Therapeutic Drug Monitoring, vol.30, issue.1, pp.113-116, 2008.
DOI : 10.1097/FTD.0b013e318161a335

J. Kovarik, S. Hartmann, and J. Figueiredo, Effect of Rifampin on Apparent Clearance of Everolimus, Annals of Pharmacotherapy, vol.15, issue.6, pp.981-985, 2002.
DOI : 10.1345/aph.1A384

R. Van-damme-lombaerts, N. Webb, and P. Hoyer, Single-dose pharmacokinetics and tolerability of everolimus in stable pediatric renal transplant patients, Pediatric Transplantation, vol.9, issue.Suppl. 2, pp.147-152, 2002.
DOI : 10.1034/j.1399-3046.2002.01070.x

P. Hoyer, R. Ettenger, and J. Kovarik, Everolimus in pediatric de nova renal transplant patients1, Transplantation, vol.75, issue.12, pp.2082-2085, 2003.
DOI : 10.1097/01.TP.0000070139.63068.54

R. Doyle, M. Hertz, and J. Dunitz, RAD in stable lung and heart/lung transplant recipients: safety, tolerability, pharmacokinetics, and impact of cystic fibrosis, The Journal of Heart and Lung Transplantation, vol.20, issue.3, pp.330-339, 2001.
DOI : 10.1016/S1053-2498(00)00232-1

A. Zuckermann, Clinical Experience With Certican?? (Everolimus) in Maintenance Heart Transplant Patients at the Medical University of Vienna, The Journal of Heart and Lung Transplantation, vol.24, issue.4, 2005.
DOI : 10.1016/j.healun.2005.01.021

R. Starling, J. Hare, and P. Hauptman, Therapeutic Drug Monitoring for Everolimus in Heart Transplant Recipients Based on Exposure-Effect Modeling, American Journal of Transplantation, vol.3, issue.5, pp.2126-2131, 2004.
DOI : 10.1056/NEJMoa021744

D. Anglicheau, E. Thervet, and I. Etienne, CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation, Clinical Pharmacology & Therapeutics, vol.75, issue.5, pp.422-455, 2004.
DOI : 10.1016/j.clpt.2004.01.009

D. Anglicheau, N. Pallet, and M. Rabant, Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine???sirolimus interaction, Kidney International, vol.70, issue.6, pp.1019-1025, 2006.
DOI : 10.1038/sj.ki.5001649

O. Cole, M. Shehata, and K. Rigg, Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model, Transplantation Proceedings, vol.30, issue.5, pp.2200-2203, 1998.
DOI : 10.1016/S0041-1345(98)00590-9

H. Schuurman, C. Pally, and G. Weckbecker, SDZ RAD inhibits cold ischemia-induced vascular remodeling, Transplantation Proceedings, vol.31, issue.1-2, pp.1024-1025, 1999.
DOI : 10.1016/S0041-1345(98)01885-5

T. Nishimura, J. Faul, and G. Berry, -(2-Hydroxyethyl)-rapamycin Attenuates Pulmonary Arterial Hypertension and Neointimal Formation in Rats, American Journal of Respiratory and Critical Care Medicine, vol.163, issue.2, pp.498-502, 2001.
DOI : 10.1164/ajrccm.163.2.2006093

M. Vigano, M. Tuzcu, and R. Benza, Prevention of Acute Rejection and Allograft Vasculopathy by Everolimus in Cardiac Transplants Recipients: A 24-Month Analysis, The Journal of Heart and Lung Transplantation, vol.26, issue.6, pp.584-592, 2007.
DOI : 10.1016/j.healun.2007.03.005

I. Etienne, O. Toupance, and A. Thierry, Benefit of a 50% Reduction of Cyclosporine Exposure in Stable Kidney Transplant Recipients Treated with MMF without Corticosteroids. The DICAM Randomized Study, Am J Transplant, vol.7, issue.52, p.207, 2007.

J. Morton, B. Mcwhinney, and P. Hickman, Therapeutic drug monitoring (TDM) of prednisolone in lung transplantation, The Journal of Heart and Lung Transplantation, vol.20, issue.2, p.192, 2001.
DOI : 10.1016/S1053-2498(00)00402-2

O. Majid, F. Akhlaghi, and T. Lee, Simultaneous Determination of Plasma Prednisolone, Prednisone, and Cortisol Levels by High-Performance Liquid Chromatography, Therapeutic Drug Monitoring, vol.23, issue.2, pp.163-168, 2001.
DOI : 10.1097/00007691-200104000-00012

P. Glander, P. Hambach, and K. Braun, Pre-Transplant Inosine Monophosphate Dehydrogenase Activity is Associated with Clinical Outcome After Renal Transplantation, American Journal of Transplantation, vol.18, issue.4
DOI : 10.1097/01.TP.0000062833.14843.4B

J. Wang, J. Yang, and A. Zeevi, IMPDH1 Gene Polymorphisms and Association With Acute Rejection in Renal Transplant Patients, Clinical Pharmacology & Therapeutics, vol.10, issue.5, pp.711-717, 2008.
DOI : 10.1038/sj.clpt.6100347

S. Hoffmann, E. Stanley, and C. Darrin, ASSOCIATION OF CYTOKINE POLYMORPHIC INHERITANCE AND IN VITRO CYTOKINE PRODUCTION IN ANTI-CD3/CD28-STIMULATED PERIPHERAL BLOOD LYMPHOCYTES1, Transplantation, vol.72, issue.8, pp.1444-1450, 2001.
DOI : 10.1097/00007890-200110270-00019

N. Kutukculer, K. Clark, and K. Rigg, THE VALUE OF POSTTRANSPLANT MONITORING OF INTERLEUKIN (IL)-2, IL-3, IL-4, IL-6, IL-8, AND SOLUBLE CD23 IN THE PLASMA OF RENAL ALLOGRAFT RECIPIENTS, Transplantation, vol.59, issue.3, pp.333-340, 1995.
DOI : 10.1097/00007890-199502000-00005

O. David, A. Johnston, and G. Cooney, SPARSE SAMPLE MEASUREMENT OF CYCLOSPORIN AUC AFTER NEORAL?? IN HEART TRANSPLANT PATIENTS., Therapeutic Drug Monitoring, vol.21, issue.4, p.447, 1999.
DOI : 10.1097/00007691-199908000-00086

M. Hale, A. Nicholls, and R. Bullingham, The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation*, Clinical Pharmacology & Therapeutics, vol.33, issue.6, pp.672-683, 1998.
DOI : 10.1016/S0009-9236(98)90058-3